Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Anca Associated Vasculitis (aav) Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

11 recruiting trials for Anca Associated Vasculitis (aav). Eligibility criteria explained in plain English.

TrialFinderData lists 11 Anca Associated Vasculitis (aav) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 33% (2 studies); the largest phase groups are Phase 1 / Phase 2: 2, Early Phase 1: 1, Phase 1: 1, Phase 2: 1.

Research is led by University of Bonn (2), Shanghai Changzheng Hospital (1), University of the West of England (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Single nucleotide polymorphisms (SNP) (diagnostic_test, 1 trial), followed by 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
11
Total Trials
11
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Track Anca Associated Vasculitis (aav) trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06696027

AYLo - AutoimmunitY and Loss of y

The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims...

Sponsor: University of BonnEnrolling: 5001 location
RECRUITINGEarly Phase 1NCT07526350

MTS109 in Patients With Refractory Autoimmune Diseases

This is the first-in-human trial of MTS109 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS109 in moderate to...

Sponsor: Shanghai Changzheng HospitalEnrolling: 151 location
RECRUITINGNCT06642870

Rare AutoImmune SElf-management Programme Development

The rare autoimmune rheumatic diseases (RAIRDs) are life-long multi-system diseases that are life or organ threatening. RAIRDs can impair quality of life similar to chronic...

Sponsor: University of the West of EnglandEnrolling: 3601 location
RECRUITINGPhase 1NCT06980597

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-108 in relapsed/refractory autoimmune diseases.

Sponsor: Beijing GoBroad HospitalEnrolling: 442 locations
RECRUITINGPhase 1 / Phase 2NCT07089121

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile...

Sponsor: Cartesian TherapeuticsEnrolling: 502 locations
RECRUITINGNCT06614270

Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

This study is a single-center, open-label, single-arm, dose-escalation trial. The aim of this study is to investigate the safety and efficacy of Anti-CD19 IL-10/IL15 CAR-NK cells...

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEnrolling: 151 location
RECRUITINGPhase 1 / Phase 2NCT06828042

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

Autoimmune diseases refer to a common category of diseases caused by the immune system reacting to self-antigens, leading to tissue damage. Autoimmune diseases encompass a wide...

Sponsor: Peking University Third HospitalEnrolling: 91 location
RECRUITINGPhase 2NCT06868290

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis...

Sponsor: Novartis PharmaceuticalsEnrolling: 12620 locations
RECRUITINGPhase 4NCT06611696

Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis

The goal of this clinical trial is to learn if avacopan in combination with short-term (4 weeks) reduced-dose glucocorticoid and rituximab works to treat patients with newly-onset...

Sponsor: Chiba UniversityEnrolling: 16020 locations
RECRUITINGNCT07258524

PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis

Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a severe autoimmune condition characterised by inflammation of small blood vessels. The condition causes...

Sponsor: University of EdinburghEnrolling: 1201 location
RECRUITINGNCT07150000

Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy

The CARe RAiSE project represents a pioneering translational initiative aimed at advancing precision medicine in the treatment of autoimmune rheumatic diseases. The primary...

Sponsor: University of BonnEnrolling: 1201 location

Frequently Asked Questions

There are currently 11 clinical trials for Anca Associated Vasculitis (aav), with 11 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Anca Associated Vasculitis (aav), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Anca Associated Vasculitis (aav), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.